The therapeutic monoclonal antibody market
D. Ecker,
S. D. Jones,
H. Levine
|
10 |
2015 |
10
2015
|
Agent-Based Modeling vs. Equation-Based Modeling: A Case Study and Users' Guide
H. V. Parunak,
R. Savit,
R. Riolo
|
9 |
1998 |
9
1998
|
The making of bispecific antibodies
U. Brinkmann,
R. Kontermann
|
9 |
2017 |
9
2017
|
Cell culture processes for monoclonal antibody production
Feng Li,
N. Vijayasankaran,
Amy Shen,
R. Kiss,
A. Amanullah
|
9 |
2010 |
9
2010
|
The immunogenicity of humanized and fully human antibodies
F. Harding,
M. Stickler,
J. Razo,
R. Dubridge
|
9 |
2010 |
9
2010
|
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
B. Kelley
|
9 |
2009 |
9
2009
|
Site-specific antibody drug conjugates for cancer therapy
S. Panowski,
S. Bhakta,
H. Raab,
P. Polakis,
Jagath R Junutula
|
9 |
2013 |
9
2013
|
Recovery and purification process development for monoclonal antibody production
Hui F. Liu,
Jun-fen Ma,
Charles M Winter,
R. Bayer
|
8 |
2010 |
8
2010
|
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
11 auth.
M. Overdijk,
S. Verploegen,
M. Bögels,
M. van Egmond,
J. J. V. van Bueren,
T. Mutis,
...
R. Groen,
E. Breij,
A. Martens,
W. Bleeker,
P. Parren
|
8 |
2015 |
8
2015
|
Disulfide bond structures of IgG molecules
Hongcheng Liu,
Kimberly M. L. May
|
8 |
2012 |
8
2012
|
Antibodies to watch in 2019
H. Kaplon,
J. Reichert
|
8 |
2018 |
8
2018
|
Dual targeting strategies with bispecific antibodies
R. Kontermann
|
8 |
2012 |
8
2012
|
Marketed therapeutic antibodies compendium
J. Reichert
|
8 |
2012 |
8
2012
|
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
H. Donaghy
|
8 |
2016 |
8
2016
|
Antibodies to watch in 2020
H. Kaplon,
Mrinalini Muralidharan,
Zita Schneider,
J. Reichert
|
8 |
2019 |
8
2019
|
From KISS to KIDS - An 'Anti-simplistic' Modelling Approach
B. Edmonds,
S. Moss
|
8 |
2004 |
8
2004
|
